Triple combination program for the treatment of cystic fibrosis receives FDA fast track designation April 5, 2018
Phase III study evaluates ASTX-727 versus intravenous decitabine in patients with MDS and CMML April 5, 2018
Corvus Pharmaceuticals initiates phase I study of CPI-006 in patients with advanced solid tumors April 5, 2018
RSS